Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03990363 · ClinicalTrials.gov registry record · Phase 2
A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 861
- Enrollment target
NCT03990363 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 861 participants.
The verdict
NCT03990363, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 861 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to establish the dose of verinurad combined with allopurinol 300 mg once daily that will elicit the desired response; ie, reduction in urinary albumin to creatinine ratio (UACR) at 6 months.
Interventions
- DRUG Allopurinol
- DRUG Verinurad
- DRUG Placebo for Verinurad
- DRUG Placebo for Allopurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 861 participants |
| Start Date | 2019-07-23 |
| Est. Completion | 2021-11-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03990363
The ClinicalTrials.gov registry entry for NCT03990363 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 861 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Allopurinol is the first listed.
NCT03990363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03990363 about?
NCT03990363 is a clinical study titled "A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia". The purpose of this clinical research study is to establish the dose of verinurad combined with allopurinol 300 mg once daily that will elicit the desired response; ie, reduction in urinary albumin to creatinine ratio (UACR) at 6 months.
What is the current status of trial NCT03990363?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 861 participants. The study started on 2019-07-23. Estimated completion is 2021-11-22.
What interventions are being tested in trial NCT03990363?
The interventions under investigation include: Allopurinol (DRUG), Verinurad (DRUG), Placebo for Verinurad (DRUG), Placebo for Allopurinol (DRUG).
Who is sponsoring clinical trial NCT03990363?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.